[go: up one dir, main page]

WO2011085071A3 - Attenuated francisella mutants and methods of use - Google Patents

Attenuated francisella mutants and methods of use Download PDF

Info

Publication number
WO2011085071A3
WO2011085071A3 PCT/US2011/020328 US2011020328W WO2011085071A3 WO 2011085071 A3 WO2011085071 A3 WO 2011085071A3 US 2011020328 W US2011020328 W US 2011020328W WO 2011085071 A3 WO2011085071 A3 WO 2011085071A3
Authority
WO
WIPO (PCT)
Prior art keywords
mutants
francisella
attenuated
methods
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/020328
Other languages
French (fr)
Other versions
WO2011085071A2 (en
Inventor
Xin-He Lai
Fred L. Heffron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health and Science University
Original Assignee
Oregon Health and Science University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health and Science University filed Critical Oregon Health and Science University
Publication of WO2011085071A2 publication Critical patent/WO2011085071A2/en
Publication of WO2011085071A3 publication Critical patent/WO2011085071A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Francisella tularensis is the bacterial pathogen that causes tularemia in humans and a number of animals. To date, no approved vaccine exists for this widespread and life-threatening disease. The present disclosure provides attenuated Francisella mutants that include genetic inactivations in two genes. The Francisella mutants contain a genetic inactivation in at least one gene selected from dsbB, FTT0742, pdpB,fumA, and carB, and at least one gene selected from tolB, htrB, ipxH, ostAl, fimT, ipcC, manB, manC, nusA, wzx, kdtA, FTN0408, FTN0757 and FTN1254. Also provided are immunogenic compositions that include the attenuated bacteria. Methods are provided for treatment (e.g., treatment of tularemia) using the attenuated Francisella mutants.
PCT/US2011/020328 2010-01-06 2011-01-06 Attenuated francisella mutants and methods of use Ceased WO2011085071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29255010P 2010-01-06 2010-01-06
US61/292,550 2010-01-06

Publications (2)

Publication Number Publication Date
WO2011085071A2 WO2011085071A2 (en) 2011-07-14
WO2011085071A3 true WO2011085071A3 (en) 2012-03-15

Family

ID=44306133

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/020328 Ceased WO2011085071A2 (en) 2010-01-06 2011-01-06 Attenuated francisella mutants and methods of use

Country Status (1)

Country Link
WO (1) WO2011085071A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12116595B2 (en) 2018-09-17 2024-10-15 The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Target-primed macrophages and therapeutic uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111019A1 (en) * 2005-04-20 2006-10-26 National Research Council Of Canada Mutant f. tularensis strain and uses thereof
WO2007035897A2 (en) * 2005-09-24 2007-03-29 President And Fellows Of Harvard College Improved live attenuated vaccine strain for prevention of tularemia
WO2007097789A1 (en) * 2006-02-23 2007-08-30 Oregon Health & Science University Attenuated francisella and methods of use
WO2007101262A2 (en) * 2006-02-28 2007-09-07 The Board Of Regents Of The University Of Texas System Attenuated francisella bacteria

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111019A1 (en) * 2005-04-20 2006-10-26 National Research Council Of Canada Mutant f. tularensis strain and uses thereof
WO2007035897A2 (en) * 2005-09-24 2007-03-29 President And Fellows Of Harvard College Improved live attenuated vaccine strain for prevention of tularemia
WO2007097789A1 (en) * 2006-02-23 2007-08-30 Oregon Health & Science University Attenuated francisella and methods of use
WO2007101262A2 (en) * 2006-02-28 2007-09-07 The Board Of Regents Of The University Of Texas System Attenuated francisella bacteria

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CLARKE, D. K. ET AL.: "Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations", JOURNAL OF VIROLOGY., vol. 81, no. 4, 6 December 2006 (2006-12-06), pages 2056 - 2064 *
KOTLOFF, K. L. ET AL.: "Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208", JOURNAL OF INFECTIOUS DISEASES., vol. 190, no. 10, 19 October 2004 (2004-10-19), pages 1745 - 1754 *

Also Published As

Publication number Publication date
WO2011085071A2 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
WO2009006453A3 (en) Enabling the use of long dsrna for gene targeting in mammalian and other selected animal cells
WO2010033798A3 (en) Live bacterial vaccines resistant to carbon dioxide (co2), acidic ph and/or osmolarity for viral infection prophylaxis or treatment
Abil et al. Synthetic biology for therapeutic applications
WO2011022435A3 (en) Biocontrol microorganisms
CA2814652C (en) Human oncostatin m antibodies and methods of use
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
WO2011106541A3 (en) Diagnostic methods involving loss of heterozygosity
MX2010002867A (en) Live attenuated mycoplasma strains.
MD4481B1 (en) Recombinant Koi herpesvirus (KHV) and vaccine for the prevention of a disease caused by KHV
Lorenz et al. Importance of flagella in acute and chronic Pseudomonas aeruginosa infections
UA115235C2 (en) Bacillus thuringiensis toxin gene axmi335 and methods for its use
WO2013030176A3 (en) Live attenuated influenza virus
Charoonnart et al. Transgenic microalgae expressing double-stranded RNA as potential feed supplements for controlling white spot syndrome in shrimp aquaculture
Amen et al. Harnessing the Microbiome: CRISPR-Based Gene Editing and Antimicrobial Peptides in Combating Antibiotic Resistance and Cancer
CA3152931A1 (en) Modulation of microbiota compositions using targeted nucleases
GB2458057A (en) Francisella strain for live vaccine
Miftakhov et al. Persistence as a Constituent of a Biocontrol Mechanism (Competition for Nutrients and Niches) in Pseudomonas putida PCL1760
WO2011139881A3 (en) Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
WO2015111075A3 (en) Method of increasing biomass and lipid content in a micro-organism and a genetically modified micro-organism exhibiting enhanced autophagy
WO2011085071A3 (en) Attenuated francisella mutants and methods of use
MX353828B (en) Composition comprising nucleic acids of parasitic, pathogenic or weed biological systems for inhibiting and/or controlling the growth of said systems.
WO2007097789A8 (en) Attenuated francisella and methods of use
Danish-Daniel et al. Draft genome sequence of Mameliella alba strain UMTAT08 isolated from clonal culture of toxic dinoflagellate Alexandrium tamiyavanichii
Lakota Synthetic Biology-Friend or Foe? What Kind of Threats Should We Expect?
Schieferecke et al. The Application of DNA Viruses to Biotechnology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11732126

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11732126

Country of ref document: EP

Kind code of ref document: A2